section name header

Pronunciation ⬇

trye-meth-oh-BEN-za-mide

Classifications ⬆ ⬇

Therapeutic Classification: antiemetics

Pharmacologic Classification: anticholinergics

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inhibits emetic stimulation of the chemoreceptor trigger zone in the medulla.
Therapeutic effects:
  • Decreased nausea and vomiting.

Pharmacokinetics ⬆ ⬇

Absorption: Complete absorption following oral and IM administration.

Distribution: Unknown.

Metabolism/Excretion: Metabolized by the liver; 30–50% excreted unchanged in urine.

Half-Life: 7–9 hr.

Time/Action Profile ⬆ ⬇

(antiemetic effect)

ROUTEONSETPEAKDURATION
PO10–40 minunknown3–4 hr
IM15–35 minunknown2–3 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension

GI: diarrhea, hepatitis

Derm: rash

Hemat: blood dyscrasias

Local: pain at injection site, burning/redness/stinging at IM injection site

Neuro: drowsiness, COMA, depression, extrapyramidal reactions, SEIZURES

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Tigan

Code ⬆

NDC Code